Lung stereotactic body radiation therapy: Regional nodal failure is not predicted by tumor size

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1693-1697

  Marwaha, Gaurav ^a   Stephans, Kevin L ^a   Woody, Neil M ^a   Reddy, Chandana A ^a   Videtic, Gregory M M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Lymph node; Non small cell lung cancer; Stage I; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INSTITUTIONAL REVIEW; LUNG LESION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT FAILURE; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION DOSE; RADIOSURGERY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84925709292     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000313     Document Type: Article

References (14)

1. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-682.
2. Timmerman R, Paulus R, GalvinJ, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
3. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-622.
4. Robinson CG, DeWees TA, El Naqa IM, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol 2013;8:192-201.
5. Nath SK, Sandhu AP, Kim D, et al. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol 2011;99:12-17.
6. Sagawa M, Saitoh Y, Takahashi S, et al. [Analysis of patients with resected small-size (less than or equal to 2 cm in diameter) peripheral type lung cancer lesions]. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:944-949.
7. Gould PM, Bonner JA, Sawyer TE, et al. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;45:91-95.
8. Edge SB, Byrd DR, Compton CC, et al. (Eds). AJCC Cancer Staging Manual. New York, NY: Springer, 2010.
9. Videtic GM, Stephans K, Reddy C, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys 2010;77:344-349.
10. Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg 2014;147:747-752.
11. Silvestri GA, Gould MK, Margolis ML, et al.; American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):178S-201S.
12. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589-595.
13. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-935.
14. Matsuo Y, Shibuya K, Nagata Y, et al. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol 2012;7:453-456.